Literature DB >> 27014791

Twenty Years of Experience in Pediatric Living Donor Liver Transplantation: Focus on Hepatic Artery Reconstruction, Complications, and Outcomes.

João Seda-Neto1, Eduardo Antunes da Fonseca, Renata Pugliese, Helry L Candido, Marcel R Benavides, Rogério Carballo Afonso, Romerito Neiva, Gilda Porta, Irene K Miura, Hsiang W Teng, Fernanda C Iwase, Mônica L Rodrigues, Luis Augusto Carneiro de Albuquerque, Mario Kondo, Paulo Chapchap.   

Abstract

BACKGROUND: Hepatic artery thrombosis (HAT) increases morbidity and mortality after liver transplantation (LT). The identification of risk factors for HAT may aid transplant teams in the development of strategies aimed at reducing HAT. This article describes the risk factors for HAT and outcomes after LT.
METHODS: This report describes a retrospective study (1995 to 2015) of primary pediatric living donor LT (LDLT). Pretransplant and technical variables were included in the study. Binary logistic regression was used for data analysis.
RESULTS: This study included 656 primary LDLT. The median age, body weight, and pediatric end-stage liver disease score at the time of transplant were 13 months, 8.4 kg and 15, respectively. Twenty-one (3.2%) patients developed HAT. Intraoperative HAT (odds ratio, 62.63; 95% confidence interval, 12.64-310.19; P < 0.001) and the use of liver grafts with a graft-to-recipient weight ratio less than 1.1% (odds ratio, 24.46; 95% confidence interval, 4.55-131.56; P < 0.001) retained statistical significance in the multivariate model. Patient and graft survivals were significantly worse in cases with HAT. The overtime trend analysis revealed a decrease in the incidence of HAT (P = 0.008) and an increase in the use of 2-arterial anastomosis (P < 0.001).
CONCLUSIONS: A graft-to-recipient weight ratio of 1.1% or less and intraoperative HAT were independently associated with HAT. Trend analysis further revealed a significant reduction in the incidence of HAT over time, as well as the increased use of 2 hepatic arteries for anastomosis during graft implantation. The double artery anastomosis may represent an extra protection to pediatric recipients undergoing LDLT.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27014791     DOI: 10.1097/TP.0000000000001135

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Risk factors of hepatic artery thrombosis in pediatric deceased donor liver transplantation.

Authors:  Nan Ma; Zhuolun Song; Chong Dong; Chao Sun; Xingchu Meng; Wei Zhang; Kai Wang; Bin Wu; Shanni Li; Hong Qin; Chao Han; Haohao Li; Wei Gao; Zhongyang Shen
Journal:  Pediatr Surg Int       Date:  2019-06-15       Impact factor: 1.827

2.  Comprehensive review of surgical microscopes: technology development and medical applications.

Authors:  Ling Ma; Baowei Fei
Journal:  J Biomed Opt       Date:  2021-01       Impact factor: 3.170

Review 3.  Evaluation and management of biliary complications after pediatric liver transplantation: pearls and pitfalls for percutaneous techniques.

Authors:  Eric J Monroe; David S Shin; Victoria A Young; Jeffrey Forris Beecham Chick; Kevin S H Koo; Andrew Woerner; Christopher R Ingraham
Journal:  Pediatr Radiol       Date:  2021-10-29

4.  Microsurgical Hepatic Artery Reconstruction Using Ikuta A-II Double Clamp.

Authors:  Masayuki Okochi; Hiromi Okochi; Takao Sakaba; Masanori Momiyama; Kazuki Ueda
Journal:  Plast Reconstr Surg Glob Open       Date:  2017-05-16

5.  Outcomes following liver transplantation in young infants: Data from the SPLIT registry.

Authors:  Ajay K Jain; Ravinder Anand; Stacee Lerret; George Yanni; Jia-Yuh Chen; Saeed Mohammad; Majella Doyle; Greg Telega; Simon Horslen
Journal:  Am J Transplant       Date:  2020-09-05       Impact factor: 8.086

6.  Predicting early outcomes of liver transplantation in young children: The EARLY study.

Authors:  Rashid Alobaidi; Natalie Anton; Dominic Cave; Elham Khodayari Moez; Ari R Joffe
Journal:  World J Hepatol       Date:  2018-01-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.